• 哈爾濱醫(yī)科大學(xué)附屬第二醫(yī)院血管外科(黑龍江哈爾濱 150086);

目的  研究半乳糖凝集素-3 (Galectin-3,Gal-3)的結(jié)構(gòu)、功能、與脂類(lèi)代謝關(guān)系及其在下肢動(dòng)脈硬化閉塞癥的發(fā)生和進(jìn)展中的表達(dá)情況。
方法  對(duì)相關(guān)文獻(xiàn)進(jìn)行綜述分析。
結(jié)果  Gal-3參與炎癥反應(yīng)及脂類(lèi)代謝紊亂,調(diào)節(jié)細(xì)胞的生長(zhǎng)、分化、黏附、凋亡和血管生成,參與動(dòng)脈硬化閉塞癥的發(fā)生和進(jìn)展。
結(jié)論  Gal-3與下肢動(dòng)脈硬化閉塞癥的發(fā)生、進(jìn)展和預(yù)后的相關(guān)性是肯定的,具有生物學(xué)標(biāo)志性意義。

引用本文: 祖紅林,張英男. 半乳糖凝集素-3與下肢動(dòng)脈硬化閉塞癥關(guān)系的研究進(jìn)展△. 中國(guó)普外基礎(chǔ)與臨床雜志, 2013, 20(4): 462-465. doi: 復(fù)制

1. 王玉琦, 岳嘉寧, 符偉國(guó). 下肢動(dòng)脈硬化閉塞癥的外科治療進(jìn)展[J]. 中華臨床醫(yī)師雜志(電子版), 2009, 3(2):179-183.
2. 劉昌偉. 下肢動(dòng)脈硬化閉塞癥的外科治療[J]. 臨床外科雜志,2006, 14(5):265-266.
3. Aronow WS. Peripheral arterial disease of the lower extremities[J]. Arch Med Sci, 2012, 8(2): 375-388.
4. Sundblad V, Croci DO, Rabinovich GA. Regulated expression of galectin-3, a multifunctional glycan-binding protein, in haematopoietic and non-haematopoietic tissues[J]. Histol Histopathol, 2011, 26(2):247-265.
5. Dumic J, Dabelic S, Flögel M. Galectins:an open-ended story[J]. Biochim Biophys Acta, 2006, 1760(4): 616-635.
6. Yang RY, Rabinovich GA, Liu FT. Galectins:structure, function and therapeutic potential[J]. Expert Rev Mol Med, 2008, 10:e17.
7. Idikio HA. Galectin-3 and Beclin1/Atg6 genes in human cancers:using cDNA tissue panel, qRT-PCR, and logistic regression modelto identify cancer cell biomarkers[J]. Plos One, 2011, 6(10):e26150.
8. Jara LJ, Medina G, Vera-Lastra O, et al. Accelerated atherosclerosis, immune response and autoimmune rheumatic diseases[J]. Autoimmun Rev, 2006, 5(3):195-201.
9. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis[J]. Circulation, 2002, 105(9):1135-1143.
10. Hsu DK, Hammes SR, Kuwabara I, et al. Human T lymphotropicvirus-I infection of human T lymphocytes induces expression of the beta-galactoside-binding lectin, galectin-3[J]. Am J Pathol, 1996,148(5):1661-1670.
11. Kimata H. Enhancement of IgE production in B cells by neutrophils via galectin-3 in IgE-associated atopic eczema/dermatitis syndrome[J]. Int Arch Allergy Immunol, 2002, 128(2):168-170.
12. Fermino ML, Polli CD, Toledo KA, et al. LPS-induced galectin-3 oligomerization results in enhancement of neutrophil activation[J]. PloS One, 2011, 6(10): e20064.
13. Novak R, Dabelic S, Dumic J. Galectin-1 and galectin-3 expre-ssion profiles in classically and alternatively activated human macrophages[J]. Biochim Biophys Acta, 2012, 1820(9): 1383-1390.
14. Paclik D, Werner L, Guckelberger O, et al. Galectins distinctively regulate central monocyte and macrophage function[J]. Cell Immunol, 2011, 271(1): 97-103.
15. Papaspyridonos M, McNeill E, de Bono JP, et al. Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progressionthrough macrophage activation and monocyte chemoattraction[J]. Arterioscler Thromb Vasc Biol, 2008, 28(3): 433-440.
16. Sano H, Hsu DK, Apgar JR, et al. Critical role of galectin-3 in phagocytosis by macrophages[J]. J Clin Invest, 2003, 112(3): 389-397.
17. Sano H, Hsu DK, Yu L, et al. Human galectin-3 is a novelchemoattractant for monocytes and macrophages[J]. J Immunol,.
18. Nachtigal M, Al-Assaad Z, Mayer EP, et al. Galectin-3 expression in human atherosclerotic lesions[J]. Am J Pathol, 1998, 152(5): 1199-1208.
19. Falcone C, Lucibello S, Mazzucchelli I, et al. Galectin-3 plasma levels and coronary artery disease: a new possible biomarker of acute coronary syndrome[J]. Int J Immunopathol Pharmacol, 2011, 24(4):905-913.
20. Vlassara H, Li YM, Imani F, et al. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products(AGE):a new member of the AGE-receptor complex[J]. Mol Med ,1995, 1(6):634-646.
21. Ahmad N, Gabius HJ, André S, et al. Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes[J]. J Biol Chem, 2004, 279(12):10841–10847.
22. Califice S, Castronovo V, Van Den Brûle F. Galectin-3 and cancer(Review)[J]. Int J Oncol, 2004, 25(4):983-992.
23. Ferrazzo KL, Neto MM, dos Santos E, et al. Differential expression of galectin-3, beta-catenin, and cyclin D1 in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma of salivary glands[J]. J Oral Pathol Med, 2009, 38(9): 701-707.
24. Lee JH, Zhang X, Shin BK, et al. Mac-2 binding protein andgalectin-3 expression in mucinous tumours of the ovary:an anne-aling control primer system and immunohistochemical study[J]. Pathology, 2009, 41(3): 229-233.
25. Miranda FA, Hassumi MK, Guimaraes MC, et al. Galectin-3 overexpression in invasive laryngeal carcinoma, assessed by computer-assisted analysis[J]. J Histochem Cytochem, 2009, 57(7):665-673.
26. Nangia-Makker P, Balan V, Raz A. Galectin-3 binding andmetastasis[J]. Methods Mol Biol, 2012, 878: 251-266.
27. Shoeppner HL, Raz A, Ho SB, et al. Expression of an endogenous galactoside-binding lectin correlates with neoplastic progression in the colon[J]. Cancer, 1995, 75(12):2818-2826.
28. Xu XC, el-Nagger AK, Lotan R. Differential expression of gale-ctin-1 and galectin-3 in thyroid tumors:potential diagnostic impli-cations[J]. Am J Pathol, 1995, 147(3): 815-822.
29. Bresalier RS, Mazurek N, Sternberg LR, et al. Metastasis of human colon cancer is altered by modifying expression of the b galactoside-binding protein galectin-3[J]. Gastroenterology, 1998, 115(2):287-296.
30. Scott A, Mellor H. VEGF receptor trafficking in angiogenesis[J]. Biochem Soc Trans, 2009, 37(Pt 6):1184-1188.
31. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors[J]. Nat Med, 2003, 9(6): 669-676.
32. Markowska AI, Liu FT, Panjwani N. Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenesis[J]. J Exp Med, 2010, 207(9): 1981-1993.
33. Takahashi T, Yamaguchi S, Chida K, et al. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelialcells[J]. EMBO J, 2001, 20(11):2768-2778.
34. Markowska AI, Jefferise KC, Panjwani N. Galectin-3 protein modulates cell surface expression and activation of vascularendothelial growth factor receptor 2 in human endothelial cells[J]. J Biol Chem, 2011, 286(34): 29913-29921.
35. Nangia-Makker P, Honjo Y, Sarvis R, et al. Galectin-3 induces endothelial cell morphogenesis and angiogenesis[J]. Am J Pathol, 2000, 156(3):899-909.
36. Saint-Lu N, Oortwijn BD, Pengon JN, et al. Identification ofgalectin-1 and galectin-3 as novel partners for von Willebrand factor[J]. Arterioscler Thromb Vasc Biol, 2012, 32(4):894-901.
37. Stowell SR, Arthur CM, Mehta P, et al. Galectin-1, -2, and-3exhibit differential recognition of sialylated glycans and blood group antigens[J]. J Biol Chem, 2008, 283(15):10109-10123.
38. , 165(4): 2156–2164.
  1. 1. 王玉琦, 岳嘉寧, 符偉國(guó). 下肢動(dòng)脈硬化閉塞癥的外科治療進(jìn)展[J]. 中華臨床醫(yī)師雜志(電子版), 2009, 3(2):179-183.
  2. 2. 劉昌偉. 下肢動(dòng)脈硬化閉塞癥的外科治療[J]. 臨床外科雜志,2006, 14(5):265-266.
  3. 3. Aronow WS. Peripheral arterial disease of the lower extremities[J]. Arch Med Sci, 2012, 8(2): 375-388.
  4. 4. Sundblad V, Croci DO, Rabinovich GA. Regulated expression of galectin-3, a multifunctional glycan-binding protein, in haematopoietic and non-haematopoietic tissues[J]. Histol Histopathol, 2011, 26(2):247-265.
  5. 5. Dumic J, Dabelic S, Flögel M. Galectins:an open-ended story[J]. Biochim Biophys Acta, 2006, 1760(4): 616-635.
  6. 6. Yang RY, Rabinovich GA, Liu FT. Galectins:structure, function and therapeutic potential[J]. Expert Rev Mol Med, 2008, 10:e17.
  7. 7. Idikio HA. Galectin-3 and Beclin1/Atg6 genes in human cancers:using cDNA tissue panel, qRT-PCR, and logistic regression modelto identify cancer cell biomarkers[J]. Plos One, 2011, 6(10):e26150.
  8. 8. Jara LJ, Medina G, Vera-Lastra O, et al. Accelerated atherosclerosis, immune response and autoimmune rheumatic diseases[J]. Autoimmun Rev, 2006, 5(3):195-201.
  9. 9. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis[J]. Circulation, 2002, 105(9):1135-1143.
  10. 10. Hsu DK, Hammes SR, Kuwabara I, et al. Human T lymphotropicvirus-I infection of human T lymphocytes induces expression of the beta-galactoside-binding lectin, galectin-3[J]. Am J Pathol, 1996,148(5):1661-1670.
  11. 11. Kimata H. Enhancement of IgE production in B cells by neutrophils via galectin-3 in IgE-associated atopic eczema/dermatitis syndrome[J]. Int Arch Allergy Immunol, 2002, 128(2):168-170.
  12. 12. Fermino ML, Polli CD, Toledo KA, et al. LPS-induced galectin-3 oligomerization results in enhancement of neutrophil activation[J]. PloS One, 2011, 6(10): e20064.
  13. 13. Novak R, Dabelic S, Dumic J. Galectin-1 and galectin-3 expre-ssion profiles in classically and alternatively activated human macrophages[J]. Biochim Biophys Acta, 2012, 1820(9): 1383-1390.
  14. 14. Paclik D, Werner L, Guckelberger O, et al. Galectins distinctively regulate central monocyte and macrophage function[J]. Cell Immunol, 2011, 271(1): 97-103.
  15. 15. Papaspyridonos M, McNeill E, de Bono JP, et al. Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progressionthrough macrophage activation and monocyte chemoattraction[J]. Arterioscler Thromb Vasc Biol, 2008, 28(3): 433-440.
  16. 16. Sano H, Hsu DK, Apgar JR, et al. Critical role of galectin-3 in phagocytosis by macrophages[J]. J Clin Invest, 2003, 112(3): 389-397.
  17. 17. Sano H, Hsu DK, Yu L, et al. Human galectin-3 is a novelchemoattractant for monocytes and macrophages[J]. J Immunol,.
  18. 18. Nachtigal M, Al-Assaad Z, Mayer EP, et al. Galectin-3 expression in human atherosclerotic lesions[J]. Am J Pathol, 1998, 152(5): 1199-1208.
  19. 19. Falcone C, Lucibello S, Mazzucchelli I, et al. Galectin-3 plasma levels and coronary artery disease: a new possible biomarker of acute coronary syndrome[J]. Int J Immunopathol Pharmacol, 2011, 24(4):905-913.
  20. 20. Vlassara H, Li YM, Imani F, et al. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products(AGE):a new member of the AGE-receptor complex[J]. Mol Med ,1995, 1(6):634-646.
  21. 21. Ahmad N, Gabius HJ, André S, et al. Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes[J]. J Biol Chem, 2004, 279(12):10841–10847.
  22. 22. Califice S, Castronovo V, Van Den Brûle F. Galectin-3 and cancer(Review)[J]. Int J Oncol, 2004, 25(4):983-992.
  23. 23. Ferrazzo KL, Neto MM, dos Santos E, et al. Differential expression of galectin-3, beta-catenin, and cyclin D1 in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma of salivary glands[J]. J Oral Pathol Med, 2009, 38(9): 701-707.
  24. 24. Lee JH, Zhang X, Shin BK, et al. Mac-2 binding protein andgalectin-3 expression in mucinous tumours of the ovary:an anne-aling control primer system and immunohistochemical study[J]. Pathology, 2009, 41(3): 229-233.
  25. 25. Miranda FA, Hassumi MK, Guimaraes MC, et al. Galectin-3 overexpression in invasive laryngeal carcinoma, assessed by computer-assisted analysis[J]. J Histochem Cytochem, 2009, 57(7):665-673.
  26. 26. Nangia-Makker P, Balan V, Raz A. Galectin-3 binding andmetastasis[J]. Methods Mol Biol, 2012, 878: 251-266.
  27. 27. Shoeppner HL, Raz A, Ho SB, et al. Expression of an endogenous galactoside-binding lectin correlates with neoplastic progression in the colon[J]. Cancer, 1995, 75(12):2818-2826.
  28. 28. Xu XC, el-Nagger AK, Lotan R. Differential expression of gale-ctin-1 and galectin-3 in thyroid tumors:potential diagnostic impli-cations[J]. Am J Pathol, 1995, 147(3): 815-822.
  29. 29. Bresalier RS, Mazurek N, Sternberg LR, et al. Metastasis of human colon cancer is altered by modifying expression of the b galactoside-binding protein galectin-3[J]. Gastroenterology, 1998, 115(2):287-296.
  30. 30. Scott A, Mellor H. VEGF receptor trafficking in angiogenesis[J]. Biochem Soc Trans, 2009, 37(Pt 6):1184-1188.
  31. 31. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors[J]. Nat Med, 2003, 9(6): 669-676.
  32. 32. Markowska AI, Liu FT, Panjwani N. Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenesis[J]. J Exp Med, 2010, 207(9): 1981-1993.
  33. 33. Takahashi T, Yamaguchi S, Chida K, et al. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelialcells[J]. EMBO J, 2001, 20(11):2768-2778.
  34. 34. Markowska AI, Jefferise KC, Panjwani N. Galectin-3 protein modulates cell surface expression and activation of vascularendothelial growth factor receptor 2 in human endothelial cells[J]. J Biol Chem, 2011, 286(34): 29913-29921.
  35. 35. Nangia-Makker P, Honjo Y, Sarvis R, et al. Galectin-3 induces endothelial cell morphogenesis and angiogenesis[J]. Am J Pathol, 2000, 156(3):899-909.
  36. 36. Saint-Lu N, Oortwijn BD, Pengon JN, et al. Identification ofgalectin-1 and galectin-3 as novel partners for von Willebrand factor[J]. Arterioscler Thromb Vasc Biol, 2012, 32(4):894-901.
  37. 37. Stowell SR, Arthur CM, Mehta P, et al. Galectin-1, -2, and-3exhibit differential recognition of sialylated glycans and blood group antigens[J]. J Biol Chem, 2008, 283(15):10109-10123.
  38. 38. , 165(4): 2156–2164.
  • 上一篇

    風(fēng)濕性心瓣膜病二尖瓣置換術(shù)中并發(fā)血管麻痹綜合征一例
  • 下一篇

    風(fēng)濕性心瓣膜病二尖瓣置換術(shù)中并發(fā)血管麻痹綜合征一例